866-997-4948(US-Canada Toll Free)

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 168 Pages


Global Markets Directs, \'Recurrent Glioblastoma Multiforme (GBM) Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM). Recurrent Glioblastoma Multiforme (GBM) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Recurrent Glioblastoma Multiforme (GBM).
  • A review of the Recurrent Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Recurrent Glioblastoma Multiforme (GBM) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Recurrent Glioblastoma Multiforme (GBM) Overview 8
Therapeutics Development 9
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Overview 9
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis 10
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 11
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 14
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Recurrent Glioblastoma Multiforme (GBM) - Products under Development by Companies 17
Recurrent Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 18
Recurrent Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 19
F. Hoffmann-La Roche Ltd. 19
Amgen Inc. 20
AstraZeneca PLC 21
Eli Lilly and Company 22
GlaxoSmithKline plc 23
Agenus, Inc. 24
Merck & Co., Inc. 25
Novartis AG 26
Eisai Co., Ltd. 27
Pfizer Inc. 28
GW Pharmaceuticals plc 29
Celldex Therapeutics, Inc. 30
ImmunoCellular Therapeutics, Ltd. 31
ThromboGenics NV 32
AngioChem Inc. 33
Ascenta Therapeutics, Inc. 34
Vascular Biogenics Ltd. 35
Archer Biosciences, Inc 36
Tocagen Inc. 37
DNAtrix, Inc. 38
ERC Belgium SA 39
OncoSynergy Inc 40
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Target 43
Assessment by Mechanism of Action 48
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Assessment by Therapeutic Class 57
Drug Profiles 60
bosutinib - Drug Profile 60
axitinib - Drug Profile 62
onartuzumab - Drug Profile 66
dacomitinib - Drug Profile 69
rindopepimut - Drug Profile 71
VB-111 - Drug Profile 72
ANG-1005 - Drug Profile 74
AT-101 - Drug Profile 76
vorinostat - Drug Profile 80
buparlisib hydrochloride - Drug Profile 83
pazopanib hydrochloride - Drug Profile 86
memantine hydrochloride - Drug Profile 90
galunisertib - Drug Profile 91
G-200 - Drug Profile 93
ERC-1671 - Drug Profile 95
lenvatinib - Drug Profile 97
trebananib - Drug Profile 100
TB-403 - Drug Profile 103
nabiximols - Drug Profile 105
golvatinib - Drug Profile 107
ARC-100 - Drug Profile 109
New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile 111
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 112
golvatinib + lenvatinib - Drug Profile 114
ICT-121 - Drug Profile 116
BTSC mRNA Loaded Dendritic Cell Vaccine - Drug Profile 117
AZD-7451 - Drug Profile 118
DNX-2401 - Drug Profile 119
OS-2966 - Drug Profile 121
Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates 122
Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects 154
Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones 155
Featured News & Press Releases 155

Appendix 165
Methodology 165
Coverage 165
Secondary Research 165
Primary Research 165
Expert Panel Validation 165
Contact Us 166
Disclaimer 166

List of Table


Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H2 2013 11
Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2013 12
Number of Products under Development by Companies, H2 2013 14
Number of Products under Development by Companies, H2 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2013 16
Comparative Analysis by Clinical Stage Development, H2 2013 17
Comparative Analysis by Early Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2013 21
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H2 2013 22
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca PLC, H2 2013 23
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2013 24
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline plc, H2 2013 25
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H2 2013 26
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co., Inc., H2 2013 27
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2013 28
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H2 2013 29
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H2 2013 30
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals plc, H2 2013 31
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics, Inc., H2 2013 32
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2013 33
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ThromboGenics NV, H2 2013 34
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H2 2013 35
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Ascenta Therapeutics, Inc., H2 2013 36
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H2 2013 37
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Archer Biosciences, Inc, H2 2013 38
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H2 2013 39
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by DNAtrix, Inc., H2 2013 40
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2013 41
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by OncoSynergy Inc, H2 2013 42
Assessment by Monotherapy Products, H2 2013 43
Assessment by Combination Products, H2 2013 44
Number of Products by Stage and Target, H2 2013 47
Number of Products by Stage and Mechanism of Action, H2 2013 52
Number of Products by Stage and Route of Administration, H2 2013 56
Number of Products by Stage and Molecule Type, H2 2013 58
Number of Products by Stage and Therapeutic Class, H2 2013 61
Recurrent Glioblastoma Multiforme (GBM) Therapeutics - Recent Pipeline Updates, H2 2013 124
Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2013 156

List of Chart

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H2 2013 11
Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2013 12
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 16
Comparative Analysis by Clinical Stage Development, H2 2013 17
Assessment by Monotherapy Products, H2 2013 43
Number of Products by Top 10 Target, H2 2013 45
Number of Products by Stage and Top 10 Target, H2 2013 46
Number of Products by Top 10 Mechanism of Action, H2 2013 50
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 51
Number of Products by Top 10 Route of Administration, H2 2013 55
Number of Products by Stage and Top 10 Route of Administration, H2 2013 56
Number of Products by Top 10 Molecule Type, H2 2013 57
Number of Products by Stage and Top 10 Molecule Type, H2 2013 58
Number of Products by Top 10 Therapeutic Class, H2 2013 59
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 60

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *